AIGH Capital Management LLC Cuts Stake in Biodesix, Inc. (NASDAQ:BDSX)

AIGH Capital Management LLC decreased its holdings in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 30.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,272,591 shares of the company's stock after selling 1,907,221 shares during the quarter. Biodesix accounts for approximately 1.1% of AIGH Capital Management LLC's holdings, making the stock its 25th biggest position. AIGH Capital Management LLC owned approximately 2.92% of Biodesix worth $2,671,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Barclays PLC raised its position in Biodesix by 387.3% in the 4th quarter. Barclays PLC now owns 112,254 shares of the company's stock worth $171,000 after buying an additional 89,218 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Biodesix by 385.9% during the 4th quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company's stock valued at $78,000 after purchasing an additional 40,524 shares during the last quarter. Samjo Management LLC purchased a new stake in shares of Biodesix during the 4th quarter valued at about $3,790,000. Northern Trust Corp increased its position in shares of Biodesix by 286.5% during the 4th quarter. Northern Trust Corp now owns 169,132 shares of the company's stock valued at $259,000 after purchasing an additional 125,368 shares during the last quarter. Finally, Susquehanna International Group LLP increased its position in shares of Biodesix by 769.8% during the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock valued at $1,707,000 after purchasing an additional 987,475 shares during the last quarter. Hedge funds and other institutional investors own 20.96% of the company's stock.

Biodesix Stock Performance

Biodesix stock traded up $0.01 during midday trading on Tuesday, hitting $0.36. The stock had a trading volume of 1,470,627 shares, compared to its average volume of 2,498,815. The firm's fifty day moving average is $0.30 and its two-hundred day moving average is $0.64. The company has a market capitalization of $52.76 million, a PE ratio of -1.24 and a beta of 0.97. Biodesix, Inc. has a 52-week low of $0.17 and a 52-week high of $2.04. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 3.32.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $17.96 million during the quarter, compared to analyst estimates of $19.50 million. Biodesix had a negative net margin of 54.28% and a negative return on equity of 167.28%. On average, research analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

BDSX has been the subject of several research reports. Canaccord Genuity Group reduced their price target on shares of Biodesix from $2.50 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Craig Hallum reduced their price target on shares of Biodesix from $3.00 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Scotiabank reduced their price target on shares of Biodesix from $3.00 to $2.00 and set a "sector outperform" rating for the company in a research report on Wednesday, May 21st. Lake Street Capital reduced their price target on shares of Biodesix from $3.00 to $2.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, William Blair reaffirmed a "market perform" rating on shares of Biodesix in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Biodesix currently has an average rating of "Moderate Buy" and a consensus price target of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.